A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison, +19

Hepatology

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

Y. Benhamou, Marie-Valérie Bochet, Vincent Thibault, +9

The Lancet

Open-label Pilot StudyViral HepatitisMedicineAntiviral Drug DevelopmentHepatitis B +8

Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol‐Induced Liver Damage, Steatosis, and Inflammation in Mice

Aditya Ambade, Patrick Lowe, Karen Kodys, +11

Hepatology

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

Maria Eugenia Guicciardi, Christy E. Trussoni, Anuradha Krishnan, +9

Journal of Hepatology

Macrophage BiologyInflammationAutoimmune DiseaseImmunologyChronic Inflammation +6

Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study

Emmanuel Gonzalès, Winita Hardikar, Michael Stormon, +17

The Lancet

MedicineAlagille SyndromeRandomised Phase 2Maralixibat Treatment

The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice

Pamela Vig, Francesco Paolo Russo, Robert J. Edwards, +5

Hepatology

Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease

Sean Emery, William B. Capra, David A. Cooper, +8

The Journal of Infectious Diseases

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

Yves Benhamou, Vincent Thibault, Pamela Vig, +9

Journal of Hepatology

Viral HepatitisMedicineLamivudine-resistant Hepatitis BAntiviral Drug DevelopmentAntiviral Therapy +9

Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population

Mette Juul Nielsen, Diana Julie Leeming, Zachary Goodman, +11

Journal of Hepatology

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study

Kathleen M. Loomes, Robert H. Squires, Déirdre Kelly, +15

Hepatology Communications

PathologyPharmacotherapyCholangiopathiesBsep DeficiencyAutoimmune Liver Disease +25